These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20707790)

  • 1. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome.
    Sand PK; Johnson Ii TM; Rovner ES; Ellsworth PI; Oefelein MG; Staskin DR
    BJU Int; 2011 Feb; 107(4):612-20. PubMed ID: 20707790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
    Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
    Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials.
    Staskin DR; Rosenberg MT; Sand PK; Zinner NR; Dmochowski RR
    Int J Clin Pract; 2009 Dec; 63(12):1715-23. PubMed ID: 19930332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.
    Ginsberg DA; Oefelein MG; Ellsworth PI
    Neurourol Urodyn; 2011 Apr; 30(4):563-7. PubMed ID: 21268101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.
    MacDiarmid SA; Ellsworth PI; Ginsberg DA; Oefelein MG; Sussman DO
    Urology; 2011 Jan; 77(1):24-9. PubMed ID: 20970833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release trospium chloride improves quality of life in overactive bladder.
    Dmochowski RR; Rosenberg MT; Zinner NR; Staskin DR; Sand PK
    Value Health; 2010; 13(2):251-7. PubMed ID: 19818062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial.
    Staskin D; Sand P; Zinner N; Dmochowski R;
    J Urol; 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4. PubMed ID: 17632131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release.
    Staskin DR; Cardozo L
    Int J Clin Pract; 2009 Jun; 63(6):973-6. PubMed ID: 19459997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trospium chloride treatment of overactive bladder.
    Biastre K; Burnakis T
    Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study.
    Dmochowski RR; Sand PK; Zinner NR; Staskin DR
    Urology; 2008 Mar; 71(3):449-54. PubMed ID: 18342185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trospium chloride and oxybutynin hydrochloride in a german study of adults with urinary urge incontinence: results of a 12-week, multicenter, randomized, double-blind, parallel-group, flexible-dose noninferiority trial.
    Zellner M; Madersbacher H; Palmtag H; Stöhrer M; Bödeker RH;
    Clin Ther; 2009 Nov; 31(11):2519-39. PubMed ID: 20109997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome.
    Sand PK; Dmochowski RR; Zinner NR; Staskin DR; Appell RA
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Dec; 20(12):1431-8. PubMed ID: 19727537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
    Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
    BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.